Roche and Eli Lilly Collaborate to Advance Elecsys Amyloid Plasma Panel for Early Alzheimer’s Diagnosis

SmartCom APP learned that Swiss pharmaceutical giant Roche (RHHBY.US) announced on Wednesday that it has reached a collaboration with Eli Lilly (LLY.US) to support the development of the Elecsys Amyloid Plasma Panel (EAPP). This move is expected to enhance the early diagnosis of Alzheimer's disease.

It is reported that EAPP is an innovative blood test designed to promote the early diagnosis of Alzheimer's disease. EAPP has demonstrated its clinical performance and is currently undergoing additional research to ensure clinical validation.

If approved, the EAPP test would serve as an additional tool to identify a low likelihood of amyloid pathology in symptomatic patients and determine whether they should undergo further evaluation and testing to confirm the diagnosis.

In July 2022, Roche announced that the U.S. Food and Drug Administration (FDA) had granted EAPP Breakthrough Device Designation.

In December last year, the company's Elecsys β-Amyloid and Elecsys Phospho-Tau assays also received FDA 510(k) clearance for identifying Alzheimer’s disease pathology in the early symptomatic stages.

Roche Diagnostics CEO Matt Sause stated: "Today, more than 55 million people are living with dementia, and this number is expected to grow to nearly 140 million by 2050. Collaboration is crucial to ensure these individuals receive timely and accurate diagnoses. The Elecsys Amyloid Plasma Panel has the potential to streamline the diagnostic process for patients, paving the way for future treatment options."